According to the research report titled ‘Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Therapeutic Area; By Indication; By Approach; By Regions; Segment Forecast, 2020 -2027‘, available with Market Study Report, global human microbiome therapeutics market is anticipated to reach USD 1,544.6 million by the year 2027.
 

Rising incidences of infectious diseases and increasing government funding are the major factors expected to drive global human microbiome therapeutics market over the forecast period. Further, increasing emphasis on early detection of diseases using microbiome, rising cases of diseases due to dysbiosis, and collaborations among companies will also stimulate the market outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963800/
 

According to trusted sources, Million Microbiome of Humans Project (MMHP) was introduced in November 2019 in collaboration with Denmark, France, China, Sweden, Latvia, and other countries to assist in meta-genomic research. The project aims to create the largest database of human microbiome by studying over a million samples accumulated from gut, reproductive tract, skin, and other organs. Such initiatives by governments and private entities are fueling global human microbiome therapeutics market trends. However, side effects related to the usage of biotherapeutics is major challenge for the industry.
 

Based on product type, global human microbiome therapeutics market is segmented into prescription drugs, prebiotics, probiotics, and medical foods. With regards to therapeutic area, the industry is bifurcated into digestive & gastrointestinal disorders, dental disorders, metabolic disorders, oncology, dermatological diseases, infectious diseases, autoimmune disorders, and others.
 

As per indication, worldwide human microbiome therapeutics industry is segmented into atopic dermatitis, lactose intolerance, clostridium difficile Infection, acne vulgaris, inflammatory bowel disease (IBD), non-alcoholic steatohepatitis (NASH), lung cancer, coeliac disease, diabetes, obesity, and colorectal cancer.
 

Speaking of the approach, global human microbiome therapeutics market landscape is bifurcated into genetically modified single strain bacteria, microbial consortia, small molecule therapies, microbial ecosystems, phage cocktail, and single strain whole bacteria.
 

Key players influencing global human microbiome therapeutics market trends are Embion Technologies, Igen Biolab Group, Evelo Biosciences, Ferring Pharmaceuticals, Vedanta Biosciences, 5QBD-Biotech, GNUbiotics Sciences, Finch Therapeutics, 4D Pharma plc, Seres Therapeutics, and Enterome Bioscience.